It is a good time to be in biotech, EBD Group and KNect365 Life Sciences managing director, Anna Chrisman, told delegates on Monday. “Deal making is off the charts and the IPO window is open – and that seems to be true in the US, Europe and Asia alike.
“The pace of innovation and the delivery of value to patients continues to accelerate and drug approvals are at an all-time high,” Chrisman added.
Biopharma-Reporter joined the biotech world in Copenhagen this week, to cover partnering trends, Chinese investment opportunities, and the ‘make or buy’ dilemma in the large molecule space.
Scroll down for live Twitter updates from the event.
